Top

Published in:

01-04-2021 | Breast Cancer | Epidemiology

Association between lincRNA expression and overall survival for patients with triple-negative breast cancer

Authors: Jie Ping, Shuya Huang, Jie Wu, Pingping Bao, Timothy Su, Kai Gu, Hui Cai, Xingyi Guo, Loren Lipworth, William J. Blot, Wei Zheng, Qiuyin Cai, Xiao-Ou Shu

Published in: Breast Cancer Research and Treatment | Issue 3/2021

Abstract

Purpose

Long intergenic non-coding RNAs (lincRNAs) are increasingly recognized as important regulators for pathogenesis and/or prognosis of breast cancer, including triple-negative breast cancer (TNBC) subtype. However, few previous studies used RNA-sequencing (RNA-Seq) technology, and none included an independent replication.

Methods

To systematically evaluate the association between expression of lincRNAs and TNBC survival, we examined lincRNA expression profiles in TNBC tissues using RNA-Seq data for 200 TNBC patients from the Shanghai Breast Cancer Survival Study (SBCSS) and Southern Community Cohort Study (SCCS).

Results

Twenty-five lincRNAs were found to be associated with overall survival (P < 0.05 and no significant heterogeneity across studies at Q statistic P > 0.1), and 61 lincRNAs were associated with disease-free survival (DFS). Among these, two lincRNAs (LINC01270 and LINC00449) were significantly associated with both worse overall survival and DFS and were expressed at significantly higher levels in tumor tissues compared with adjacent normal breast tissues (log₂[Fold Change] > 0.5 and FDR < 0.05). We further evaluated the potential functions of LINC01270 and LINC00449 using in vitro functional experiments and found that siRNA-mediated knockdown of LINC01270 and LINC00449 expression significantly decreased cell viability, colony formation and cell migration ability in TNBC cells (P < 0.05).

Conclusions

Evidence from observational studies and in vitro experiments indicates that LINC00449 and LINC01270 may be prognostic biomarkers for TNBC.

Available only for authorised users

Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, Cabili MN, Jaenisch R, Mikkelsen TS, Jacks T, Hacohen N, Bernstein BE, Kellis M, Regev A, Rinn JL, Lander ES (2009) Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458(7235):223–227. https://doi.org/10.1038/nature07672CrossRefPubMedPubMedCentral

Preker P, Nielsen J, Kammler S, Lykke-Andersen S, Christensen MS, Mapendano CK, Schierup MH, Jensen TH (2008) RNA exosome depletion reveals transcription upstream of active human promoters. Science 322(5909):1851–1854. https://doi.org/10.1126/science.1164096CrossRefPubMed

Han P, Chang CP (2015) Long non-coding RNA and chromatin remodeling. RNA Biol 12(10):1094–1098. https://doi.org/10.1080/15476286.2015.1063770CrossRefPubMedPubMedCentral

Hadjicharalambous MR, Lindsay MA (2019) Long non-coding RNAs and the innate immune response. Noncoding RNA 5(2):34. https://doi.org/10.3390/ncrna5020034CrossRefPubMedCentral

Huarte M, Rinn JL (2010) Large non-coding RNAs: missing links in cancer? Hum Mol Genet 19(R2):R152–161. https://doi.org/10.1093/hmg/ddq353CrossRefPubMedPubMedCentral

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492CrossRefPubMed

Anders C, Carey LA (2008) Understanding and treating triple-negative breast cancer. Oncology 22(11):1233–1239 (discussion 1239-1240, 1243)PubMed

Kim J, Piao HL, Kim BJ, Yao F, Han Z, Wang Y, Xiao Z, Siverly AN, Lawhon SE, Ton BN, Lee H, Zhou Z, Gan B, Nakagawa S, Ellis MJ, Liang H, Hung MC, You MJ, Sun Y, Ma L (2018) Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet 50(12):1705–1715. https://doi.org/10.1038/s41588-018-0252-3CrossRefPubMedPubMedCentral

Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, Vidi PA, Tyagi A, Chan MD, Ruiz J, Debinski W, Pasche BC, Lo HW, Metheny-Barlow LJ, D’Agostino RB Jr, Watabe K (2018) Loss of XIST in breast cancer Activates MSN-c-met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res 78(15):4316–4330. https://doi.org/10.1158/0008-5472.CAN-18-1102CrossRefPubMedPubMedCentral

10.

Shin VY, Chen J, Cheuk IW, Siu MT, Ho CW, Wang X, Jin H, Kwong A (2019) Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. Cell Death Dis 10(4):270. https://doi.org/10.1038/s41419-019-1513-5CrossRefPubMedPubMedCentral

11.

Ding X, Zhu L, Ji T, Zhang X, Wang F, Gan S, Zhao M, Yang H (2014) Long intergenic non-coding RNAs (LincRNAs) identified by RNA-seq in breast cancer. PLoS ONE 9(8):e103270. https://doi.org/10.1371/journal.pone.0103270CrossRefPubMedPubMedCentral

12.

Zhang Y, Wagner EK, Guo X, May I, Cai Q, Zheng W, He C, Long J (2016) Long intergenic non-coding RNA expression signature in human breast cancer. Sci Rep 6:37821. https://doi.org/10.1038/srep37821CrossRefPubMedPubMedCentral

13.

Baglia ML, Cai Q, Zheng Y, Wu J, Su Y, Ye F, Bao PP, Cai H, Zhao Z, Balko J, Zheng W, Lu W, Shu XO (2014) Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome. Breast Cancer Res Treat 148(1):211–220. https://doi.org/10.1007/s10549-014-3127-zCrossRefPubMedPubMedCentral

14.

Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, Cai Q, Lu W, Shu XO (2011) Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer 11:292. https://doi.org/10.1186/1471-2407-11-292CrossRefPubMedPubMedCentral

15.

Signorello LB, Hargreaves MK, Steinwandel MD, Zheng W, Cai Q, Schlundt DG, Buchowski MS, Arnold CW, McLaughlin JK, Blot WJ (2005) Southern community cohort study: establishing a cohort to investigate health disparities. J Natl Med Assoc 97(7):972–979PubMedPubMedCentral

16.

Guo Y, Wu J, Zhao S, Ye F, Su Y, Clark T, Sheng Q, Lehmann B, Shu XO, Cai Q (2016) RNA sequencing of formalin-fixed, paraffin-embedded specimens for gene expression quantification and data mining. Int J Genomics 2016:9837310. https://doi.org/10.1155/2016/9837310CrossRefPubMedPubMedCentral

17.

TCGA GDC mRNA analysis pipeline. https://docs.gdc.cancer.gov/Data/Bioinformatics_Pipelines/Expression_mRNA_Pipeline/

18.

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29(1):15–21. https://doi.org/10.1093/bioinformatics/bts635CrossRefPubMed

19.

Frankish A, Diekhans M, Ferreira AM, Johnson R, Jungreis I, Loveland J, Mudge JM, Sisu C, Wright J, Armstrong J, Barnes I, Berry A, Bignell A, Carbonell Sala S, Chrast J, Cunningham F, Di Domenico T, Donaldson S, Fiddes IT, Garcia Giron C, Gonzalez JM, Grego T, Hardy M, Hourlier T, Hunt T, Izuogu OG, Lagarde J, Martin FJ, Martinez L, Mohanan S, Muir P, Navarro FCP, Parker A, Pei B, Pozo F, Ruffier M, Schmitt BM, Stapleton E, Suner MM, Sycheva I, Uszczynska-Ratajczak B, Xu J, Yates A, Zerbino D, Zhang Y, Aken B, Choudhary JS, Gerstein M, Guigo R, Hubbard TJP, Kellis M, Paten B, Reymond A, Tress ML, Flicek P (2019) GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res 47(D1):D766–D773. https://doi.org/10.1093/nar/gky955CrossRefPubMed

20.

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167. https://doi.org/10.1200/JCO.2008.18.1370CrossRefPubMedPubMedCentral

21.

Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, Tse GM, Factor RE, Collins LC, Allison KH, Chen YY, Jensen K, Johnson NB, Oesterreich S, Mills GB, Cherniack AD, Robertson G, Benz C, Sander C, Laird PW, Hoadley KA, King TA, Network TR, Perou CM (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163(2):506–519. https://doi.org/10.1016/j.cell.2015.09.033CrossRefPubMedPubMedCentral

22.

Gendoo DM, Ratanasirigulchai N, Schroder MS, Pare L, Parker JS, Prat A, Haibe-Kains B (2016) Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics 32(7):1097–1099. https://doi.org/10.1093/bioinformatics/btv693CrossRefPubMed

23.

NCI GDC data portal. https://portal.gdc.cancer.gov/

24.

Mounir M, Lucchetta M, Silva TC, Olsen C, Bontempi G, Chen X, Noushmehr H, Colaprico A, Papaleo E (2019) New functionalities in the TCGAbiolinks package for the study and integration of cancer data from GDC and GTEx. PLoS Comput Biol 15(3):e1006701. https://doi.org/10.1371/journal.pcbi.1006701CrossRefPubMedPubMedCentral

25.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408. https://doi.org/10.1006/meth.2001.1262CrossRefPubMed

26.

Wu L, Wang J, Cai Q, Cavazos TB, Emami NC, Long J, Shu XO, Lu Y, Guo X, Bauer JA, Pasaniuc B, Penney KL, Freedman ML, Kote-Jarai Z, Witte JS, Haiman CA, Eeles RA, Zheng W, the Practical CBPCCPC (2019) Identification of novel susceptibility loci and genes for prostate cancer risk: a transcriptome-wide association study in over 140,000 European descendants. Cancer Res 79(13):3192–3204. https://doi.org/10.1158/0008-5472.CAN-18-3536CrossRefPubMedPubMedCentral

27.

Wu H, Liu Y, Shu XO, Cai Q (2016) MiR-374a suppresses lung adenocarcinoma cell proliferation and invasion by targeting TGFA gene expression. Carcinogenesis 37(6):567–575. https://doi.org/10.1093/carcin/bgw038CrossRefPubMedPubMedCentral

28.

Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550. https://doi.org/10.1186/s13059-014-0550-8CrossRefPubMedPubMedCentral

29.

Wang Y, Fu J, Wang Z, Lv Z, Fan Z, Lei T (2019) Screening key lncRNAs for human lung adenocarcinoma based on machine learning and weighted gene co-expression network analysis. Cancer Biomark 25(4):313–324. https://doi.org/10.3233/CBM-190225CrossRefPubMed

30.

Zahnow CA (2009) CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med 11:e12. https://doi.org/10.1017/S1462399409001033CrossRefPubMedPubMedCentral

31.

Bentires-Alj M, Neel BG (2007) Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res 67(6):2420–2424. https://doi.org/10.1158/0008-5472.CAN-06-4610CrossRefPubMed

32.

Schimmoller F, Diaz E, Muhlbauer B, Pfeffer SR (1998) Characterization of a 76 kDa endosomal, multispanning membrane protein that is highly conserved throughout evolution. Gene 216(2):311–318. https://doi.org/10.1016/s0378-1119(98)00349-7CrossRefPubMed

33.

Abou-Sharieha S, Sugii Y, Tuoya YuD, Chen L, Tokutaka H, Seno M (2009) Identification of TM9SF2 as a candidate of the cell surface marker common to breast carcinoma cells. Chin J Clin Oncol 6:1CrossRef

34.

Riba A, Emmenlauer M, Chen A, Sigoillot F, Cong F, Dehio C, Jenkins J, Zavolan M (2017) Explicit modeling of siRNA-dependent on- and off-target repression improves the interpretation of screening results. Cell Syst 4(2):182–193. https://doi.org/10.1016/j.cels.2017.01.011CrossRefPubMed

35.

Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, Linsley PS (2006) Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA 12(7):1179–1187. https://doi.org/10.1261/rna.25706CrossRefPubMedPubMedCentral

Title: Association between lincRNA expression and overall survival for patients with triple-negative breast cancer
Authors: Jie Ping
Shuya Huang
Jie Wu
Pingping Bao
Timothy Su
Kai Gu
Hui Cai
Xingyi Guo
Loren Lipworth
William J. Blot
Wei Zheng
Qiuyin Cai
Xiao-Ou Shu
Publication date: 01-04-2021
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 3/2021
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-06021-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2021

Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression

Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study

Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer

Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

The INTEND 1 randomized controlled trial of duct endoscopy as an indicator of margin excision in breast conservation surgery

Keynote webinar | Spotlight on antibody–drug conjugates in cancer